Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ)
CNY 2.36
(-1.26%)
CNY 2.36
(-1.26%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.15 Billion CNY | -22.62% |
| 2022 | 4.07 Billion CNY | -13.23% |
| 2021 | 4.69 Billion CNY | 3.96% |
| 2020 | 4.51 Billion CNY | -29.52% |
| 2019 | 6.4 Billion CNY | -32.39% |
| 2018 | 9.47 Billion CNY | 4.56% |
| 2017 | 9.06 Billion CNY | 4.59% |
| 2016 | 8.66 Billion CNY | 4.19% |
| 2015 | 8.31 Billion CNY | 68.99% |
| 2014 | 4.92 Billion CNY | 67.26% |
| 2013 | 2.94 Billion CNY | 14.75% |
| 2012 | 2.56 Billion CNY | 10.91% |
| 2011 | 2.31 Billion CNY | 5.37% |
| 2010 | 2.19 Billion CNY | 395.95% |
| 2009 | 442.47 Million CNY | 58.47% |
| 2008 | 279.2 Million CNY | 29.56% |
| 2007 | 215.51 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.07 Billion CNY | -2.3% |
| 2024 Q2 | 2.84 Billion CNY | -7.78% |
| 2024 Q3 | 2.82 Billion CNY | -0.46% |
| 2023 Q3 | 3.55 Billion CNY | -1.61% |
| 2023 Q4 | 3.15 Billion CNY | -11.43% |
| 2023 FY | 3.15 Billion CNY | -22.62% |
| 2023 Q1 | 3.94 Billion CNY | -3.09% |
| 2023 Q2 | 3.61 Billion CNY | -8.38% |
| 2022 Q3 | 4.5 Billion CNY | -1.24% |
| 2022 FY | 4.07 Billion CNY | -13.23% |
| 2022 Q4 | 4.07 Billion CNY | -9.66% |
| 2022 Q2 | 4.56 Billion CNY | 0.73% |
| 2022 Q1 | 4.53 Billion CNY | -3.45% |
| 2021 FY | 4.69 Billion CNY | 3.96% |
| 2021 Q4 | 4.69 Billion CNY | -6.08% |
| 2021 Q1 | 4.87 Billion CNY | 7.83% |
| 2021 Q2 | 4.92 Billion CNY | 1.05% |
| 2021 Q3 | 4.99 Billion CNY | 1.58% |
| 2020 Q2 | 5.43 Billion CNY | -5.9% |
| 2020 Q4 | 4.51 Billion CNY | -10.98% |
| 2020 FY | 4.51 Billion CNY | -29.52% |
| 2020 Q1 | 5.77 Billion CNY | -9.86% |
| 2020 Q3 | 5.07 Billion CNY | -6.67% |
| 2019 Q1 | 9.36 Billion CNY | -1.18% |
| 2019 FY | 6.4 Billion CNY | -32.39% |
| 2019 Q4 | 6.4 Billion CNY | -33.29% |
| 2019 Q3 | 9.6 Billion CNY | 0.71% |
| 2019 Q2 | 9.53 Billion CNY | 1.84% |
| 2018 Q4 | 9.47 Billion CNY | 1.24% |
| 2018 Q3 | 9.36 Billion CNY | -0.49% |
| 2018 FY | 9.47 Billion CNY | 4.56% |
| 2018 Q1 | 9.33 Billion CNY | 2.95% |
| 2018 Q2 | 9.4 Billion CNY | 0.81% |
| 2017 Q4 | 9.06 Billion CNY | -0.35% |
| 2017 FY | 9.06 Billion CNY | 4.59% |
| 2017 Q1 | 8.67 Billion CNY | 0.15% |
| 2017 Q2 | 8.83 Billion CNY | 1.75% |
| 2017 Q3 | 9.09 Billion CNY | 2.99% |
| 2016 Q2 | 8.25 Billion CNY | 1.3% |
| 2016 Q1 | 8.14 Billion CNY | -2.04% |
| 2016 Q4 | 8.66 Billion CNY | 2.72% |
| 2016 Q3 | 8.43 Billion CNY | 2.21% |
| 2016 FY | 8.66 Billion CNY | 4.19% |
| 2015 Q1 | 7.03 Billion CNY | 42.95% |
| 2015 FY | 8.31 Billion CNY | 68.99% |
| 2015 Q3 | 8.02 Billion CNY | 8.89% |
| 2015 Q4 | 8.31 Billion CNY | 3.68% |
| 2015 Q2 | 7.36 Billion CNY | 4.72% |
| 2014 Q4 | 4.92 Billion CNY | 15.13% |
| 2014 Q3 | 4.27 Billion CNY | -1.35% |
| 2014 FY | 4.92 Billion CNY | 67.26% |
| 2014 Q1 | 3.65 Billion CNY | 24.12% |
| 2014 Q2 | 4.33 Billion CNY | 18.65% |
| 2013 Q2 | 2.77 Billion CNY | 2.35% |
| 2013 Q4 | 2.94 Billion CNY | 3.49% |
| 2013 FY | 2.94 Billion CNY | 14.75% |
| 2013 Q1 | 2.71 Billion CNY | 5.78% |
| 2013 Q3 | 2.84 Billion CNY | 2.42% |
| 2012 Q4 | 2.56 Billion CNY | 0.53% |
| 2012 FY | 2.56 Billion CNY | 10.91% |
| 2012 Q3 | 2.55 Billion CNY | 4.98% |
| 2012 Q2 | 2.43 Billion CNY | 3.18% |
| 2012 Q1 | 2.35 Billion CNY | 1.86% |
| 2011 Q3 | 2.21 Billion CNY | 1.83% |
| 2011 Q1 | 2.14 Billion CNY | -2.18% |
| 2011 Q4 | 2.31 Billion CNY | 4.52% |
| 2011 FY | 2.31 Billion CNY | 5.37% |
| 2011 Q2 | 2.17 Billion CNY | 1.21% |
| 2010 Q2 | 2.19 Billion CNY | 379.53% |
| 2010 Q3 | 2.16 Billion CNY | -1.42% |
| 2010 Q4 | 2.19 Billion CNY | 1.42% |
| 2010 FY | 2.19 Billion CNY | 395.95% |
| 2010 Q1 | 457.73 Million CNY | 3.45% |
| 2009 Q4 | 442.47 Million CNY | 0.0% |
| 2009 FY | 442.47 Million CNY | 58.47% |
| 2008 FY | 279.2 Million CNY | 29.56% |
| 2007 FY | 215.51 Million CNY | 0.0% |